WATERTOWN, Mass., Sept. 28, 2016 -- For the seventh year in a row, pediatricians ranked temporal artery thermometry (TAT) number one in overall preference over any other thermometry method, according to a recent survey of physicians. Of the 268 survey respondents, 40.5 percent ranked TAT number one based on overall performance, compared to rectal, ear, oral and axillary thermometry. In addition, more than half (57.3 percent) of pediatricians ranked TAT number one in ease of use.
The new study further shows that Exergen is used and recommended more than any other thermometer brand – 42 percent of pediatricians use the Exergen TAT and 36 percent recommend it to their patients, ranking highest in both categories. In addition, the results show that nearly two-thirds of pediatricians (64.4 percent) who use or recommend Exergen temporal artery thermometers do so for patients of all ages, the highest percentage of any thermometer.
“We are pleased to see that pediatricians continue to embrace and recommend temporal artery thermometry over all other methods, and that the number of those physicians is steadily increasing,” said Dr. Francesco Pompei, CEO of Exergen Corporation. "With more than 60 clinical studies supporting its accuracy, physicians have come to trust and rely on the TemporalScanner. It is non-invasive, easy to use and accurate, which enhances the physician-patient bond."
Survey respondents noted strengths of temporal artery thermometry, including ease of use and accuracy. The survey also captured pediatricians' commentary about temporal artery thermometry. According to one physician respondent, "Temporal Artery Exergen has made my life very easy!" Another respondent said, “Temporal Artery is easy to use for nurse, patient and family.”
The survey was conducted by Pragmatic Research, Inc. and pediatricians were not told that it was sponsored by Exergen. The results were consistent with other independent research involving nurses and other healthcare professionals in various clinical settings.
ABOUT EXERGEN CORPORATION
Exergen Corporation is a recognized world leader in industrial and medical non-invasive temperature technology. The company manufactures and markets TemporalScanner thermometer models for hospitals and clinics, and consumer models sold in major retailers nationwide. Nearly two billion temperatures are taken each year with Exergen TemporalScanners in thousands of hospitals, clinics and pediatricians' offices across the country, as well as in millions of homes. It is the #1 preference of pediatricians, nurses, and mothers and is the #1 selling retail thermometer. The Exergen TemporalScanner’s performance is supported by more than 60 peer-reviewed published studies covering all ages from preterm infants to geriatrics, and all care areas from hospitals to homes. For additional information, visit www.exergen.com.
Contact: Victoria Day Rosica Public Relations [email protected] P: 201.843.5600 F: 201.843.5680 21-00 Route 208 South, Suite 130 Fair Lawn, NJ 07410


SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Britain Courts Anthropic Amid US Defense Department Dispute
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
First Western Ship Transits Strait of Hormuz Since Iran War Began
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 



